Modality
ERT
MOA
Anti-Aβ
Target
FXIa
Pathway
Notch
ThymomaETACC
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
→ Jan 2026
Phase 2Current
NCT07234026
2,697 pts·Thymoma
2025-01→2026-01·Terminated
NCT04116138
2,981 pts·ET
2019-06→TBD·Not yet recruiting
5,678 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-075mo agoBTD· ACC
2026-01-103mo agoPh2 Data· Thymoma
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Not yet…
P2
Termina…
Catalysts
BTD
2025-11-07 · 5mo ago
ACC
Ph2 Data
2026-01-10 · 3mo ago
Thymoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07234026 | Phase 2 | Thymoma | Terminated | 2697 | CfB |
| NCT04116138 | Phase 2 | ET | Not yet recr... | 2981 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |